Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 65/100

Failure Rate

15.7%

291 terminated/withdrawn out of 1849 trials

Success Rate

79.4%

-7.2% vs industry average

Late-Stage Pipeline

13%

247 trials in Phase 3/4

Results Transparency

50%

565 of 1122 completed trials have results

Key Signals

261 recruiting565 with results197 terminated94 withdrawn

Enrollment Performance

Analytics

N/A

809(53.2%)

Phase 2

264(17.3%)

Phase 4

180(11.8%)

Phase 1

174(11.4%)

Phase 3

67(4.4%)

Early Phase 1

28(1.8%)

1522Total

N/A(809)

Phase 2(264)

Phase 4(180)

Phase 1(174)

+2 more

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (1849)

Showing 20 of 1849 trials

NCT03872180Phase 2Active Not Recruiting

Bendamustine, Obinutuzumab, and Venetoclax in Patients With Untreated Mantle Cell Lymphoma

Role: lead

NCT01665378Not ApplicableCompleted

Impact of Pre-pregnancy Micronutrient Supplementation on Maternal and Child Outcomes

Role: lead

NCT07140679Phase 2Recruiting

Immunotherapy (Toripalimab) for Reducing Recurrence Risk After Surgery for Mismatch Repair Deficient Stage IIB, IIC, or III Colon Cancer

Role: lead

NCT03719131Phase 2Completed

Rituximab and Hyaluronidase Human in Patients With Advanced Melanoma Undergoing Nivolumab and Ipilimumab Therapy

Role: lead

NCT07332143Phase 2Recruiting

Psilocybin-Assisted Therapy

Role: lead

NCT02422875Enrolling By Invitation

Comparative Autoantibody and Immunologic Cell Marker Study

Role: lead

NCT06615375Phase 2Completed

A Human Challenge Study to Assess Protection of a Shigella Tetravalent Bioconjugate Vaccine

Role: collaborator

NCT05200208Not ApplicableCompleted

Improving Sleep and Cognition in Alzheimer's Disease

Role: lead

NCT07852650Phase 1Recruiting

Digital STEADI Efficacy

Role: collaborator

NCT05998135Phase 2Recruiting

Repurposing Atovaquone for the Treatment of Platinum-Resistant Ovarian Cancer

Role: lead

NCT06423326Phase 2Recruiting

Gemcitabine, Cisplatin and Nab-Paclitaxel as Neoadjuvant Treatment for Patients With Resectable or Borderline Resectable Pancreatic Cancer

Role: collaborator

NCT06171737Not ApplicableEnrolling By Invitation

Promoting Shared Decision Making for Severe Aortic Stenosis

Role: collaborator

NCT06492954Phase 1Recruiting

Atezolizumab in Combination With Stereotactic Body Radiation Therapy (SBRT) and Surgery for Relapsed Osteosarcoma

Role: lead

NCT06674863Not ApplicableRecruiting

Addressing Health Literacy With a Tailored Survivorship Care Plan

Role: lead

NCT07003997Phase 2Recruiting

JAK Signaling in Depression

Role: lead

NCT02944682Not ApplicableCompleted

Household Air Pollution and Health: A Multi-country LPG Intervention Trial

Role: lead

NCT04621279Recruiting

Cool Prime Comparative Effectiveness Study for Mild HIE

Role: collaborator

NCT04340882Phase 2Active Not Recruiting

Phase 2 DoceRamPem for Patients With Metastatic or Recurrent NSCLC Who Progressed on Platinum-Doublet and PD-1/PD-L1 Blockade

Role: lead

NCT07608796Phase 2Recruiting

JAK Signaling in Depression and Cognition in Male Football Players

Role: lead

NCT07468695Not ApplicableNot Yet Recruiting

Feasibility Study Comparing Use of One Or Two Probes for Thermal Ablation Among Cervical Cancer Screen Positive Women Living With HIV in C1001P-CS2 Kenya

Role: collaborator